A Sub-pharmacological Test Dose Does Not Predict Individual Docetaxel Exposure in Prostate Cancer Patients

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2024 Jul 1

PMID 38951305

Authors

Marise R Heerma van Voss

Jessica Notohardjo

Joyce van Dodewaard-de Jong

Haiko J Bloemendal

Rob Ter Heine

Affiliations

Soon will be listed here.

Abstract

Purpose: Docetaxel is a cytotoxic drug used for first-line treatment of various malignancies. It has a narrow therapeutic index and shows wide interpatient variability in clearance and toxicity. Tools for individual dose optimization are needed to maximize efficacy and avoid toxicity.

Methods: We performed a proof-of-concept study (EudraCT 2016-003785-77) to evaluate whether pharmacokinetics after a sub-pharmacological test dose of 1000 µg docetaxel (millidose) could be used to predict therapeutic dose exposure. Thirty prostate cancer patients eligible for treatment with docetaxel as part of routine clinical care were included. An intravenous docetaxel millidose was administered 1-7 days prior to therapeutic docetaxel. After both doses plasma docetaxel concentrations were measured by ultra- high performance liquid chromatography-tandem mass spectrometry. The docetaxel clearance was estimated with non-linear mixed effects modeling.

Results: Geometric mean docetaxel clearance was 57.9 L/h (GCV 78.6%) after admission of a millidose and 40.3 L/h (GCV 60.7%) after admission of a therapeutic dose. The millidose and therapeutic dose in a single patient were not significantly correlated (Spearman's rho R = 0.02, P = 0.92).

Conclusion: Docetaxel pharmacokinetics at milli- and therapeutic dose level showed insufficient correlation for individual dose optimization. However, the clearance of a docetaxel millidose and full dose are within the same order of magnitude. Therefore, docetaxel millidose pharmacokinetics could potentially facilitate prediction of docetaxel pharmacokinetics at a population level in situations where therapeutic dose levels are impractical, such as pharmacokinetic drug-drug interaction studies or pediatric studies.

References

Puisset F, Alexandre J, Treluyer J, Raoul V, Roche H, Goldwasser F . Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer. 2007; 97(3):290-6. PMC: 2360335. DOI: 10.1038/sj.bjc.6603872. View

Fujita K, Yoshino E, Kawara K, Maeda K, Kusuhara H, Sugiyama Y . A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Cancer Chemother Pharmacol. 2015; 76(4):793-801. DOI: 10.1007/s00280-015-2844-2. View

van der Heijden L, van Nuland M, Beijnen J, Huitema A, Dorlo T . A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens. Clin Transl Sci. 2022; 16(2):258-268. PMC: 9926085. DOI: 10.1111/cts.13446. View

Byon W, Smith M, Chan P, Tortorici M, Riley S, Dai H . Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e51. PMC: 6483270. DOI: 10.1038/psp.2013.26. View

Boosman R, de Rouw N, Huitema A, Burgers J, Ter Heine R . Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study. Br J Clin Pharmacol. 2022; 89(2):699-704. DOI: 10.1111/bcp.15520. View

Crown J, OLeary M . The taxanes: an update. Lancet. 2000; 355(9210):1176-8. DOI: 10.1016/S0140-6736(00)02074-2. View

van der Veldt A, Lubberink M, Mathijssen R, Loos W, Herder G, Greuter H . Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography. Clin Cancer Res. 2013; 19(15):4163-73. DOI: 10.1158/1078-0432.CCR-12-3779. View

Lombard A, Mistry H, Aarons L, Ogungbenro K . Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol. 2020; 87(4):2053-2063. DOI: 10.1111/bcp.14614. View

Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K . Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci. 2008; 100(1):144-9. PMC: 11158642. DOI: 10.1111/j.1349-7006.2009.00992.x. View

10.

Crombag M, Dorlo T, van der Pan E, van Straten A, Bergman A, van Erp N . Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharm Res. 2019; 36(12):181. DOI: 10.1007/s11095-019-2706-4. View

11.

Engels F, Loos W, van der Bol J, de Bruijn P, Mathijssen R, Verweij J . Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res. 2011; 17(2):353-62. DOI: 10.1158/1078-0432.CCR-10-1636. View

12.

Bruno R, Vivier N, Vergniol J, De Phillips S, Montay G, Sheiner L . A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996; 24(2):153-72. DOI: 10.1007/BF02353487. View

13.

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024):1163-77. PMC: 4800035. DOI: 10.1016/S0140-6736(15)01037-5. View

14.

Felici A, Verweij J, Sparreboom A . Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002; 38(13):1677-84. DOI: 10.1016/s0959-8049(02)00151-x. View

15.

Clarke S, Rivory L . Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999; 36(2):99-114. DOI: 10.2165/00003088-199936020-00002. View

16.

Rowland M . Microdosing: a critical assessment of human data. J Pharm Sci. 2012; 101(11):4067-74. DOI: 10.1002/jps.23290. View

17.

Kushnir I, Mallick R, Ong M, Canil C, Bosse D, Koczka K . Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. Cancer Chemother Pharmacol. 2020; 85(5):863-868. DOI: 10.1007/s00280-020-04063-7. View

18.

Lappin G, Noveck R, Burt T . Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol. 2013; 9(7):817-34. PMC: 4532546. DOI: 10.1517/17425255.2013.786042. View

19.

Bosgra S, Vlaming M, Vaes W . To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics. Clin Pharmacokinet. 2015; 55(1):1-15. DOI: 10.1007/s40262-015-0308-9. View

20.

Hirth J, Watkins P, Strawderman M, Schott A, Bruno R, Baker L . The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000; 6(4):1255-8. View